Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Rewards can be parsed into a motivational component ('wanting'), which relies mainly on the brain's dopaminergic system, and a hedonic component ('liking'), which relies on the opioidergic system. The observation of animal facial and behavioral reactions to rewards (e.g. pleasant tastes) has played a crucial role for our understanding of the neurochemical bases of reward processing. In adult humans, however, implicit facial reactions to reward anticipation and consumption are rarely reported, and the role that the dopaminergic and opioidergic systems play in human facial reactions to rewards remains largely unknown. It is also unclear, if human facial reactions to different types of rewards have the same neurochemical basis. To answer these questions, we conducted a study using a randomized, double-blind, betweensubject design in which 131 volunteers (88 females) received orally either the D2/D3 receptor antagonist amisulpride (400 mg), the non-selective opioid receptor antagonist naltrexone (50 mg), or placebo. Explicit (ratings and physical effort) and implicit (facial EMG) reactions to matched primary social and nonsocial rewards were assessed on a trial-by-trail basis. Sweet milk with different concentrations of chocolate flavor served as nonsocial food reward. Gentle caresses to the forearm, delivered by the same-sex experimenter at different speeds, served as social reward. Results suggested 1) reduced wanting of rewards after administration of both dopamine and opioid receptor antagonists, compared to placebo, as indicated by less physical effort produced to obtain the announced reward and increased negative facial reactions during reward anticipation; 2) reduced liking of rewards only after administration of the opioid receptors antagonist, compared to placebo, as indicated by reduced positive and increased negative facial reactions during and following reward consumption. Most drug effects were either stronger or restricted to food trials, suggesting that wanting and liking of both social and nonsocial rewards may only partially share the same neurochemical brain substrates. The results are in line with the distinction of wanting and liking by current theories of reward, and underline the importance of assessing implicit facial reactions when conducting research on reward processing in adult human participants.
Rewards can be parsed into a motivational component ('wanting'), which relies mainly on the brain's dopaminergic system, and a hedonic component ('liking'), which relies on the opioidergic system. The observation of animal facial and behavioral reactions to rewards (e.g. pleasant tastes) has played a crucial role for our understanding of the neurochemical bases of reward processing. In adult humans, however, implicit facial reactions to reward anticipation and consumption are rarely reported, and the role that the dopaminergic and opioidergic systems play in human facial reactions to rewards remains largely unknown. It is also unclear, if human facial reactions to different types of rewards have the same neurochemical basis. To answer these questions, we conducted a study using a randomized, double-blind, betweensubject design in which 131 volunteers (88 females) received orally either the D2/D3 receptor antagonist amisulpride (400 mg), the non-selective opioid receptor antagonist naltrexone (50 mg), or placebo. Explicit (ratings and physical effort) and implicit (facial EMG) reactions to matched primary social and nonsocial rewards were assessed on a trial-by-trail basis. Sweet milk with different concentrations of chocolate flavor served as nonsocial food reward. Gentle caresses to the forearm, delivered by the same-sex experimenter at different speeds, served as social reward. Results suggested 1) reduced wanting of rewards after administration of both dopamine and opioid receptor antagonists, compared to placebo, as indicated by less physical effort produced to obtain the announced reward and increased negative facial reactions during reward anticipation; 2) reduced liking of rewards only after administration of the opioid receptors antagonist, compared to placebo, as indicated by reduced positive and increased negative facial reactions during and following reward consumption. Most drug effects were either stronger or restricted to food trials, suggesting that wanting and liking of both social and nonsocial rewards may only partially share the same neurochemical brain substrates. The results are in line with the distinction of wanting and liking by current theories of reward, and underline the importance of assessing implicit facial reactions when conducting research on reward processing in adult human participants.
Altered reward processing is thought to characterize binge‐type eating disorders, but the exact nature of these alterations is unclear. A more fine‐grained understanding of whether specific aspects of reward processing contribute to the development or maintenance of binge eating may point to new therapeutic targets and personalized treatments. The incentive sensitization theory of addiction proposes that repeated use of a substance increases the desire to approach a reward (‘wanting’) but not pleasure when consuming the reward (‘liking’), suggesting that reward processes driving addiction change over time. We hypothesize that the same may be true for binge eating. Further, consistent with the maladaptive scaling hypothesis, reward processing may be heightened for multiple reinforcers in at‐risk individuals but become tuned toward food once binge eating is initiated. In this article, we propose a mechanistic staging model of reward processing in binge‐type eating disorders that synthesizes existing data and posits that alterations of reward processing depend on illness stage and reward type. We outline translational methods for testing key hypotheses and discuss clinical implications. Considering reward processing alterations in relation to illness stage has the potential to improve treatment outcomes by ensuring that the mechanisms targeted are personalized to the individual patient. Public Significance Individuals with binge‐type eating disorders experience alterations in their desire for, and pleasure from, food. We believe that the exact nature of these alterations in reward processing change over the course of illness—from the at‐risk state to an established illness. If true, treatments for binge‐type eating disorders that target reward processing should be personalized to the illness stage of the patient.
Rewards are a broad category of stimuli inducing approach behavior to aid survival. Extensive evidence from animal research has shown that wanting (the motivation to pursue a reward) and liking (the pleasure associated with its consumption) are mostly regulated by dopaminergic and opioidergic activity in dedicated brain areas. However, less is known about the neuroanatomy of dopaminergic and opioidergic regulation of reward processing in humans, especially when considering different types of rewards (i.e., social and nonsocial). To fill this gap of knowledge, we combined dopaminergic and opioidergic antagonism (via amisulpride and naltrexone administration) with functional neuroimaging to investigate the neurochemical and neuroanatomical bases of wanting and liking of matched nonsocial (food) and social (interpersonal touch) rewards, using a randomized, between‐subject, placebo‐controlled, double‐blind design. While no drug effect was observed at the behavioral level, brain activity was modulated by the administered compounds. In particular, opioid antagonism, compared to placebo, reduced activity in the medial orbitofrontal cortex during consumption of the most valued social and nonsocial rewards. Dopamine antagonism, however, had no clear effects on brain activity in response to reward anticipation. These findings provide insights into the neurobiology of human reward processing and suggest a similar opioidergic regulation of the neural responses to social and nonsocial reward consumption.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2025 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.